文献速递眼底病与葡萄膜炎

早期玻璃体切除术与全视网膜光凝及玻璃体腔注射雷珠单抗治疗增殖性糖尿病视网膜病变的成本评估

Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
PubMed 文献 · Ophthalmology · 2018-03-29

本研究基于糖尿病视网膜病变临床研究网络S方案数据构建决策分析模型,比较无糖尿病性黄斑水肿的增殖性糖尿病视网膜病变行早期玻璃体切除术(PPV)、全视网膜光凝(PRP)和玻璃体腔注射雷珠单抗(IVR)的成本-效用。结果显示早期PPV的成本-效用与PRP相似,短期优于IVR,且该优势在计入终生成本后仍持续。

要点

  • 2年每QALY成本:PRP组163 988美元(非设施102 559美元),IVR组436 992美元(326 424美元),PPV组181 144美元(107 965美元)。
  • 敏感性分析显示,若PPV组78%(设施)和80%(非设施)患者需额外IVR治疗(10.1次注射),IVR与PPV的2年每QALY成本相当。
  • 超过2年后每QALY成本:PRP组61 695美元(21 752美元),IVR组338 348美元(239 741美元),PPV组63 942美元(22 261美元)。

核心结论

  • 早期PPV作为无黄斑水肿的PDR治疗策略,其成本-效用与PRP管理相似,短期成本-效用优于IVR。
  • 计入终生成本后,PPV相对于IVR的成本-效用优势持续存在。

研究设计与样本

  • 成本-效用的决策分析模型,基于糖尿病视网膜病变临床研究网络S方案比较PRP与IVR(0.3 mg)治疗无黄斑水肿PDR的结果,模拟各治疗场景的2年总成本和结局。
  • 将上述数值与早期PPV治疗PDR的2年假设成本进行比较,使用美国医疗保险和医疗补助服务中心数据计算医院/设施和非设施环境下的模拟成本。
  • 基于保留的视觉效用和估计的剩余生命年计算成本-效用,并模拟所有场景的终生治疗成本以计算终生每QALY成本,同时进行敏感性分析评估模型假设的影响。

主要发现

  • 2年效用下每QALY的模拟治疗成本在设施(非设施)环境中:PRP组163 988美元(102 559美元),IVR组436 992美元(326 424美元),PPV组181 144美元(107 965美元)。
  • 敏感性分析显示,若PPV组78%(设施)和80%(非设施)患者需要额外IVR治疗(剂量为S方案中的10.1次注射),则IVR组与PPV组在最初2年的每QALY成本相当。
  • 超过2年后,设施(非设施)环境下的每QALY成本:PRP组61 695美元(21 752美元),IVR组338 348美元(239 741美元),PPV组63 942美元(22 261美元)。

关键数值与推荐

  • 2年每QALY成本(设施/非设施):PRP组163 988美元/102 559美元,IVR组436 992美元/326 424美元,PPV组181 144美元/107 965美元。
  • 超过2年每QALY成本(设施/非设施):PRP组61 695美元/21 752美元,IVR组338 348美元/239 741美元,PPV组63 942美元/22 261美元。
  • 敏感性分析阈值:PPV组需额外IVR治疗的比例为78%(设施)和80%(非设施%)时,IVR与PPV的2年每QALY成本相当,IVR剂量按S方案的10.1次注射。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate costs and cost-utility of early vitrectomy (pars plana vitrectomy [PPV]) compared with panretinal photocoagulation (PRP) and intravitreal ranibizumab (IVR) for proliferative diabetic retinopathy (PDR) without diabetic macular edema. DESIGN: A decision analysis model of cost-utility. PARTICIPANTS: There were no participants. METHODS: A decision analysis was based on results from the Diabetic Retinopathy Clinical Research Network Protocol S comparing treatment of PRP with IVR (0.3 mg) in PDR without incident macular edema to model the total 2-year costs and outcomes for each treatment scenario. These values were compared with the 2-year hypothetical costs of early PPV for PDR. Centers for Medicare and Medicaid Services data were used to calculate associated modeled costs in a hospital/facility-based and nonfacility setting. Cost-utility was calculated on the basis of the preserved visual utility and estimated life years remaining. In addition, costs for lifetime treatment were modeled for all scenarios and used to calculate lifetime quality-adjusted life years (QALY) costs for each scenario. Sensitivity analyses were performed to evaluate the impact of the model's assumptions. MAIN OUTCOME MEASURES: Cost of treatment, utility, and cost per QALY. RESULTS: The modeled cost per QALY of treatment for PDR for 2 years of utility in the facility (nonfacility) setting was $163 988 ($102 559) in the PRP group, $436 992 ($326 424) in the IVR group, and $181 144 ($107 965) in the PPV group. Sensitivity analysis showed that both IVR and PPV groups would have equivalent costs per QALY over the first 2 years if 78% (facility) and 80% (nonfacility) of patients in the PPV group required additional treatment with IVR (at the dose of 10.1 injections as in Protocol S). Beyond 2 years, the cost per QALY in the facility (nonfacility) setting was calculated as $61 695 ($21 752) in the PRP group, $338 348 ($239 741) in the IVR group, and $63 942 ($22 261) in the PPV group. CONCLUSIONS: Early PPV as a strategy for treatment of PDR without macular edema demonstrates cost-utility similar to management with PRP and more favorable cost-utility compared with IVR in the short term. This advantage over IVR continues when lifetime costs are factored.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Lin J, Chang JS, Yannuzzi NA, et al. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. Ophthalmology. 2018. PMID: 29606379. doi:10.1016/j.ophtha.2018.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。